Dr. Donglin Sun | Prostate Cancer | Best Researcher Award

Southern Medical University | China

AUTHOR PROFILE

🔬SUN DONGLIN – MEDICAL DOCTOR IN ONCOLOGY

📚EARLY ACADEMIC PURSUITS

Sun Donglin began his academic journey at No.1 Middle School of Fuyang, Anhui Province (2005-2008). His strong foundation in science led him to pursue a Bachelor’s Degree in Clinical Medicine at Bengbu Medical College (2008-2013), where he developed a keen interest in oncology. His dedication and passion for medical research culminated in a PhD in Oncology through the Master-Doctor Continuous Program at the Affiliated Cancer Hospital of Guangzhou Medical University (2018-2023). He was recognized as an “Outstanding Graduate Student” and “Excellent Graduate”, a testament to his academic excellence and research contributions.

🏥PROFESSIONAL ENDEAVORS

Sun Donglin’s clinical training and professional career reflect a steady progression in expertise:

2013 – 2016: Surgical Resident, Third Affiliated Hospital of Sun Yat-sen University – Gained hands-on experience in surgical oncology.
2016 – 2018: Urology Resident Physician, Shenzhen Hospital of Southern Medical University – Developed a specialization in urological oncology.
2023 – Present: Urology Associate Chief Physician, Shenzhen Hospital of Southern Medical University – Achieved Associate Chief Physician Certification in 2020, demonstrating his leadership in urologic oncology and clinical excellence.

🔍RESEARCH FOCUS

Sun Donglin’s research focuses on two critical areas in oncology:

Mechanisms of Non-Canonical NF-κB Signaling in Renal Fibrosis – Investigating how alternative pathways of NF-κB contribute to fibrosis, which has significant implications for kidney disease treatments.
Drug Resistance Mechanisms in Prostate Cancer – Exploring molecular resistance pathways in prostate cancer to enhance therapeutic strategies and overcome treatment barriers.

💡CONTRIBUTIONS TO SCIENTIFIC RESEARCH

Sun Donglin has led and participated in several high-impact research projects:

Principal Investigator:
- National Natural Science Foundation of China (Youth Program) – 300,000 RMB (2025-2027) (Approval No.: 82400789)
- Guangdong Provincial Medical Science and Technology Research Fund – 10,000 RMB (2024-2026) (Approval No.: A2024317)
- Southern Medical University National Natural Science Foundation Cultivation Program – 100,000 RMB (2024-2026) (Approval No.: 23H3AGZR02)
Key Participant in Major Research Projects:
- National Natural Science Foundation of China Major Research Program Cultivation Project – 680,000 RMB (2020-2022) (Approval No.: 91949102)
- National Natural Science Foundation of China General Program – 570,000 RMB (2019-2022) (Approval No.: 81874095)

🌍IMPACT AND INFLUENCE 🌍

Sun Donglin’s research has contributed to a deeper understanding of renal fibrosis mechanisms and drug resistance in prostate cancer. His work has the potential to improve therapeutic interventions and patient outcomes, particularly in treatment-resistant prostate cancer cases. His collaborations in major national projects highlight his role as an emerging leader in oncological research.

🏅ACADEMIC CITES AND RECOGNITION

Recognized as an Outstanding Graduate Student and Excellent Graduate during his PhD.
His research findings are gaining recognition in top-tier oncology journals, further solidifying his influence in the field.
Contributions to multi-million RMB-funded research projects, showcasing his ability to secure competitive grants.

🌱LEGACY AND FUTURE CONTRIBUTIONS

Sun Donglin’s work will shape the future of oncology therapeutics and urological oncology. His research on non-canonical NF-κB signaling could unlock new pathways for renal fibrosis treatment, while his studies on prostate cancer drug resistance could lead to novel therapeutic strategies.

Moving forward, he aims to:
✅ Expand research collaborations internationally to enhance the impact of his studies.
✅ Develop translational therapies targeting NF-κB signaling in fibrosis and prostate cancer.
✅ Mentor young oncologists and researchers to foster the next generation of medical scientists.

🌍CONCLUSION

Dr. Sun Donglin is a rising leader in oncology research and urological oncology, with a strong foundation in both clinical practice and scientific innovation. His expertise in non-canonical NF-κB signaling in renal fibrosis and drug resistance in prostate cancer has positioned him as a key contributor to the advancement of cancer therapeutics.

📊🔬NOTABLE PUBLICATION:

Title: Serum RelB is correlated with renal fibrosis and predicts chronic kidney disease progression
Authors: Sun, D., Xie, N., Wang, X., Wu, W., Li, X. Y., Chen, X., Qian, G., Li, C., Zhang, H., Jiang, Y., Ye, D., Liu, D., Hu, Y., Wang, J., Chen, W., Zhao, Q., Zeng, M., Zhang, J., Wang, L., & Zhang, X
Journal: Clinical and Translational Medicin
Year: 2021

Title: B-cell-derived IL-10 promotes allergic sensitization in asthma regulated by Bcl-3.
Authors: Qian, G., Jiang, W., Sun, D., Sun, Z., Chen, A., Fang, H., Wang, J., Liu, Y., Yin, Z., Wei, H., Fang, H., & Zhang, X.
Journal: Cellular & Molecular Immunology
Year: 2023

Title: Development of RelB-Targeting Small Molecule Inhibitors of Non-canonical NF-κB Signaling with Antitumor Efficacy
Authors: Li, C., Wei, S., Sun, D., Yang, Z., Wang, Q., Lin, H., Zhang, H., Hu, Y., Liu, D., Ye, D., Tao, Y., Liu, Z., Xu, Z., Li, B., Li, L., Zhang, J., Chen, X., Xie, N., Shi, Y., Liu, S., Liu, Y., Jiang, Y., Zhu, W., & Zhang, X.
Journal: Molecular Therapy
Year: 2025

Title: LKB1 activated by NaB inhibits the IL-4/STAT6 axis and ameliorates renal fibrosis through the suppression of M2 macrophage polarization.
Authors: Liang, W., Wu, H., Long, Q., Lin, H., Lv, X., Ma, W., Wu, T., Ai, L., Zheng, Q., Guo, J., Chen, X., Guo, J., & Sun, D..
Journal: Life Sciences
Year: 2025

Title: Integrative analysis of potential diagnostic markers and therapeutic targets for glomerulus-associated diabetic nephropathy based on cellular senescence
Authors: Sun, D., Wei, S., Wang, D., Zeng, M., Mo, Y., Li, H., Liang, C., Li, L., Zhang, J. W., & Wang, L
Journal: Frontiers in Immunology
Year: 2023

Author Profile

📚 Biography: Dr. Stavros Melemenidis

🎓 Education

DPhil in Radiation Biology – University of Oxford, Dept. Radiation Oncology, Oxford, UK (2010-2015)
- Mentors: Prof. Nicola Sibson, Prof. Ruth Muschel
- Thesis: Development of molecular targeted imaging methods for the detection of lung metastasis and angiogenesis
M.Sc. in Radiation Biology – University of Oxford, Dept. Radiation Oncology, Oxford, UK (2009-2010)
M.Sc. in Radiometrics – University of Liverpool, Dept. Physics, Liverpool, UK (2008-2009)
B.Sc. in Physics: Medical Applications – University of Liverpool, Dept. Physics, Liverpool, UK (2005-2008)
A.Eng. in PC Systems and Peripheral Equipment – IIEK Neapoleos, Technical College, Thessaloniki, Greece (1998-2000)
Cert. Medical Physics – UCLA, Dept. Radiation Oncology, Los Angeles, CA, USA (2022-2023)

🏢 Current Position

Director of Pre-clinical Radiotherapy – Dept. of Radiation Oncology, Stanford University (Jan 2023-present)
Research Scientist – Div. of Radiation Therapy, Stanford University (Feb 2020-present)

🔬 Research Experience & Skills

Stanford University, Dept. Radiation Oncology, Stanford, CA
- Director of Pre-clinical Radiotherapy Core (Jun 2023-present)
  - Calibration of preclinical orthovoltage irradiators
  - Monthly and annual quality checks for dosimetric consistency
  - Innovation in animal radiation shielding via 3D design and additive manufacturing
- Basic Life Research Scientist at Div. of Radiation Therapy (Jun 2020-present)
  - Pioneering preclinical ultra-high dose-rate (FLASH) irradiation experiments
  - Specializing in 3D-designed radiation shielding for animal safety
  - Expertise in dosimetry using radiochromic film and ion chambers
  - Development of animal models involving tumor implantation and microsurgical techniques
- Postdoctoral Fellow (Feb 2016-Jun 2020)
  - Advisor: Edward E. Graves
  - Led development of in vivo mouse tumor models integrating imaging, radiotherapy, and immunotherapy
  - Specialized in ultrasound-guided injection techniques
  - Conducted research into immune cell migration with a focus on macrophage imaging
  - Evaluated radioprotective strategies for healthy tissue through drug development
- Postdoctoral Fellow at University of Oxford, Dept. Radiation Oncology (Jan 2015-Sep 2015)
  - Advisor: Nicola R. Sibson
  - Designed and evaluated innovative imaging probes for metastasis detection and angiogenesis visualization
  - Developed dual MRI/PET probe for metastasis and MRI probe for angiogenesis
  - Managed international research collaboration with Duke University

📜 Selected Publications

In vivo PET detection of lung micrometastasis by targeting endothelial VCAM-1. Int J Mol Sci, 2024.
Multi-institutional audit of FLASH and conventional dosimetry with a 3D-printed anatomically realistic mouse phantom. Int J Radiat Oncol Biol Phys, 2023.
Exploring deep learning for estimating the isoeffective dose of FLASH irradiation from mouse intestinal histological images. J Radiat Oncol Biol Phys, 2023.
Human enteroids as a tool to study conventional and ultra-high dose rate radiation. Integr Biol (Camb), 2023.
Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1. J Clin Invest, 2023.

🏆 Awards & Honors

Recognition of Excellent Research: Aegean Conferences: 12th International Conference on Complement Therapeutics, Rhodes, Greece, 2019
Poster Prize: Aegean Conferences: 3rd International Conference for Tumor Microenvironment and Cellular Stress, Greece, Mykonos, 2014

🗣️ Conference Presentations

Oral Presentation: Demonstrating FLASH effectiveness against CONV dose rates, 34th ACRO Summit, Orlando, FL, March 2024
Poster Presentation: Anatomically Realistic 3D Printed Mouse Phantom for Multi-Institutional Benchmarking of FLASH and CONV Irradiation, 65th ASTRO Annual Meeting San Diego, USA, Oct 2023

📞 References

Prof. Billy W Loo Jr: Professor of Radiation Oncology (Radiation Therapy), Stanford University School of Medicine
Prof. Edward E Graves: Associate Professor of Radiation Oncology and Director of Molecular Imaging Program, Stanford University School of Medicine
Prof. Frederick M Dirbas: Associate Professor of Surgery (General Surgery), Stanford University School of Medicine

Dr. Stavros Melemenidis is a distinguished figure in radiation oncology, with a profound impact on preclinical radiotherapy and FLASH irradiation research. His contributions to innovative imaging techniques and his dedication to advancing cancer treatment methodologies are reflected in his extensive publication record and numerous accolades.

Donglin Sun | Prostate Cancer | Best Researcher Award